Panel Discussion on FLOW CHEMISTRY
Continuous flow chemistry, which had been used in petrochemical and fine chemicals industry for
Continuous flow chemistry, which had been used in petrochemical and fine chemicals industry for
Click HERE to download the PDF
CALIFORNIA UNIVERSITY LAB MOVES TO REDUCE WATER USAGE Asynt reports how the implementation of
What drives successful outsourcing relationships between drug innovators and contract manufacturers? When it comes to small molecule drug substance manufacturing, a combination of company size and structure, internal needs, and external factors shape the criteria drug innovators use to choose their CDMO. Data from Industry Standard Research offers insight on CDMO selection metrics for outsourced API manufacturing over the past five years and ideas on why these metrics may have changed during that time.
Supply chains are increasingly complex, particularly within the pharmaceutical and healthcare supply chain. Incoming legislation around supply chain transparency, such as the German Supply Chain Act, and the growing interest in Environmental, Social, and Governance (ESG) has led to new expectations for companies to understand their suppliers and the ESG risks of their purchasing practices. These new expectations are known as responsible procurement and seek to build ESG risks and impacts into standard procurement processes. The goal of responsible procurement is to improve the ethical, environmental, and social performance of suppliers and ultimately mitigate any negative impacts found within the supply chain. Only through a collaborative and industry-wide approach can responsible procurement create positive impact at scale and through the continued engagement of procurement professionals and support for the wider supply chain.
The war in Ukraine has created a humanitarian crisis, with countless deaths and millions of people forced to flee their homes. The war has also had a huge impact on access to medicines. There have been reports that a children’s hospital was rapidly running out of essential drugs to treat children with cancer. The WHO also warned that medical oxygen supplies across the country are dangerously low. Patients with chronic conditions will struggle to gain access to the drugs they need and screening programs have also been forced to close. Despite assurances that Russian sanctions won’t include essential medicines, they will likely also make it hard for patients there to access the drugs they require. Then there are the supply chain issues to consider, particularly in neighbouring countries. How will war affect the ability to safely transport medicines? How will it impact the ability to adequately treat the millions of refugees from the war? All wars bring suffering and inevitably the vulnerable suffer most. As the first major war on European soil in decades, the situation in Ukraine is a stark reminder of the importance of finding collaborative and creative solutions to help patients in need. The article discusses the many challenges of war, looking back on previous wars and their impact on patients, and reports on the effects the Ukraine war is having on patients in the country and beyond. It also looks at how the industry might collaborate to try to mitigate the healthcare disaster in the area.
The pharmaceutical industry is rightfully lauded for its innovation. In fact, we choose to use the word “innovator” to describe the companies that develop new therapies..
Pharma companies may make mistakes during drug development but if they apply only a temporary solution to the problem, this can just lead to the error being repeated. So how can we work more effectively and ensure we are not repeating the mistakes of the past? Helen Lowe at Arriello outlines a best-practice approach, showing how Corrective Action Preventive Action (CAPA) management provides a structure to uncover the root causes of problems, solve them and build solutions, as well as look for potential problems that might arise in the future. Effectiveness checks then allow for the review of such preventive measures to ensure that what you have put in place works for the long-term benefit of the company.
As we have witnessed over the last two years, when functioning correctly, global supply chains broaden access to critical medicines for billions around the world. Yet any number of situations, from macro events like the ongoing pandemic, the 2010 volcanic eruption in Iceland, geopolitical instability, or simply patient misunderstandings, can lead to expensive and often unnecessary wastage.
The European Medicines Agency (EMA) recently confirmed that the UNICOM’s DADI (Digital Application Dataset Integration) project will be used for regulatory data submissions. The move may have been surprising, but it offers opportunities as well as challenges for the pharma industry, says Amplexor’s Renato Rjavec.